TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tempest Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.60−0.02 (-3.86%)
Close on Oct 19, 2026
- Market cap
- $9.14M
- P/E (TTM)
- –
- Dividend yield
- –
Tempest Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.89M | $166.30M |
| Enterprise Value | $8.11M | $88.19M |
Income (trailing twelve months)
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$40.64M | -$21.40M |
| Net Income | -$40.47M | -$22.46M |
| EBITDA | -$40.64M | -$16.91M |
| EPS (Diluted) | -$4.48 | -$0.83 |
Returns
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -931.1% | -53.2% |
| Return on Assets (ROA) | -237.3% | -40.9% |
| Return on Capital Employed (ROCE) | -784.2% | -38.1% |
Balance sheet
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $779.00K | $61.43M |
| Net Cash (Debt) | $779.00K | $15.35M |
| Net Cash Per Share | $0.05 | $0.66 |
| Equity (Book Value) | -$1.09M | $49.09M |
| Book Value Per Share | -$0.07 | $1.37 |
| Tangible Book Value | -$1.09M | $23.52M |
| Working Capital | -$2.75M | $76.81M |
Financial position
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.38 | 3.34 |
| Quick Ratio | 0.18 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$20.73M | -$12.35M |
| Capital Expenditures | $0 | -$1.08M |
| Free Cash Flow | -$20.73M | -$20.22M |
| FCF Per Share | -$1.40 | -$0.42 |
Efficiency
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$10.12M | -$703.34K |
| Employee Count | 4 | 74 |
Dividends and yields
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -455.5% | -23.3% |
| FCF Yield | -233.3% | -8.72% |
Shares
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 14,807,000 | 58,127,000 |
| Shares Change (YoY) | 186.8% | 10.9% |
| Shares Change (QoQ) | 11.4% | 0.54% |
| Float | 9,032,390 | 49,136,700 |
| Shares Held by Insiders | 39.0% | 11.6% |
| Shares Held by Institutions | 6.92% | 59.4% |
Taxes
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Tempest Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -53.78 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Tempest Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.